
Exokinetics Launches Project ELEVATE Mobility Foundation -- Empowering Those in Need of Mobility Solutions
PHILADELPHIA, PA, UNITED STATES, April 16, 2025 / EINPresswire.com / -- Exokinetics, a leading mobility technology company and manufacturer of the groundbreaking Zeen mobility device, has officially launched its affiliate charitable foundation, Project ELEVATE Mobility (PEM). The PEM foundation helps provide life-changing Zeen devices to underserved individuals facing mobility challenges, empowering them with greater freedom, safety, and independence in their daily lives.
Project ELEVATE Mobility is driven by a clear mission: help those who suffer from mobility loss and financial hardship to acquire the state-of-the-art Zeen mobility device. Zeen enables users to transition from sitting to standing, allowing them to walk upright, fully supported, hands-free, and without the fear of falling—transforming lives for individuals previously confined to a wheelchair or reliant on unstable walkers and canes ( See a Zeen Demo ).
What sets Zeen apart is its revolutionary, non-motorized lift system, which gently raises users from a seated position to standing, providing safe, supported mobility while walking. Ideal for people with limited strength, balance, or endurance due to chronic conditions or injuries, the Zeen allows individuals to engage with their surroundings at eye level and perform everyday activities like cooking, reaching high shelves, or interacting socially.
Zeen is proudly made in the USA and retails for approximately $5,000—an investment that is often not currently covered by insurance. Through PEM, accepted applicants receive generous grants matching up to $2,500 of an individual's contribution toward the purchase of their Zeen. This dollar-for-dollar matching creates a partnership, fostering a sense of ownership and dignity during the process.
'We created Zeen to help individuals safely reclaim their independence, mobility, and quality of life,' said Garrett Brown, creator of Steadicam® and Founder of Exokinetics. 'Our goal is to ensure that users can engage with the world around them at eye-level, without the fear of falling, while maintaining or regaining their physical strength and confidence.'
The Zeen is suitable for children and adults weighing between 50 and 250 lbs, offering a unique solution for those experiencing mobility challenges from conditions such as Parkinson's disease, multiple sclerosis (MS), cerebral palsy, ataxia, or recovering from a stroke or injury. By promoting weight-bearing on the legs, walking with an upright posture, and reducing the fear of falling, Zeen supports overall health including cardiovascular function, muscle tone, digestion, and psychological well-being.
Looking ahead, Project ELEVATE Mobility is committed to expanding its reach and supporting as many individuals as possible living with mobility challenges.
For more information or to see a Zeen demonstration webinar (offered daily), please visit the website at GoZeen.com.
About Exokinetics
Exokinetics is a leading mobility technology company focused on restoring independence, mobility, and an active lifestyle to individuals affected by chronic conditions, age, or injury. The Zeen® is a revolutionary mobility device that helps users transition from sitting to standing and walking with ease and safety. Designed and manufactured in the USA, Zeen fills the gap between a wheelchair and a walker, offering a unique solution for individuals seeking greater mobility freedom in their daily lives.
Jonathan Abramson
Bluetone Marketing and PR
+1 619-807-6349
[email protected]
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
5 minutes ago
- Business Upturn
The Enterprise World Honors Danielle Gronich as a Leading Entrepreneur in Wellness for 2025
By GlobeNewswire Published on June 6, 2025, 18:00 IST San Diego, June 06, 2025 (GLOBE NEWSWIRE) — Danielle Gronich, widely known as The Acne Guru® and CEO of CLEARSTEM Skincare, has been featured in The Enterprise World as part of its prestigious annual issue: ' The Most Impressive Entrepreneurs Leading the Wellness Industry in 2025 .' This special edition celebrates visionary leaders who are driving innovation, transforming health and beauty standards, and redefining what wellness means in today's world. Recognized for her breakthrough contributions to skincare science and holistic acne treatment, Gronich stands among a select group of trailblazers shaping the future of the wellness industry. Who is Danielle Gronich ? Danielle Gronich is a licensed clinical esthetician, researcher, and founder of the San Diego Acne Clinic. Known as The Acne Guru®, she is the Co-Founder and CEO of CLEARSTEM Skincare, a brand that merges clean beauty with clinical results. Her work is revolutionizing the way we understand acne, aging, and internal wellness. What Readers will Gain from this Story? In this cover story readers will discover how Danielle Gronich's real-world journey—from battling cystic acne to co-founding CLEARSTEM—proves that success is less about having a flawless plan and more about taking bold, intentional steps toward solving real problems. This story offers valuable takeaways for: Aspiring entrepreneurs , showing that impactful businesses often start with a simple idea and grow through listening, learning, and adapting. , showing that impactful businesses often start with a simple idea and grow through listening, learning, and adapting. Wellness-conscious consumers , who will learn how CLEARSTEM blends clinical research with holistic health to deliver clean, effective acne and anti-aging solutions. , who will learn how CLEARSTEM blends clinical research with holistic health to deliver clean, effective acne and anti-aging solutions. Skincare professionals and enthusiasts , gaining insight into the science-backed innovation behind products like the MINDBODYSKIN supplement and CELLRENEW serum. , gaining insight into the science-backed innovation behind products like the supplement and serum. Anyone struggling with acne, finding hope in CLEARSTEM's unique approach that treats skin from the inside out, backed by education, lab testing, and expert formulation. Above all, the piece emphasizes a powerful message: You don't need the perfect plan to make a difference—you just need to start. About The Enterprise World The Enterprise World is a business magazine that serves as a platform for prominent business leaders to share their journeys to success, including the challenges and breakthroughs that shaped their paths to becoming industry stars. Attachments CLEARSTEM Skincare Danielle Gronich – The Acne Guru® The Enterprise World The Most Impressive Entrepreneur Leading the Wellness Industry in 2025 | The Enterprise World Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

Yahoo
41 minutes ago
- Yahoo
Quanterix to Present at Goldman Sachs Global Healthcare Conference
BILLERICA, Mass., June 06, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be accessed from the Investors section of the company's website at A replay of the webcast will be available for a limited period following the conference. To learn more about Quanterix, visit To learn more about Quanterix's Simoa® technology, visit About Quanterix From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn. View source version on Contacts Media Contact: Marissa Klaassenmedia@ Investor Relations Contact: Joshua Youngir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases
STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating Aspaveli® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress. In the VALIANT study, Aspaveli demonstrated a statistically significant 68% proteinuria reduction versus placebo at Week 26, which was sustained at one year. Additionally, patients treated with Aspaveli continued to achieve stabilization of kidney function as measured by estimated glomerular filtration rate (eGFR). "The one-year Phase 3 results are very compelling, confirming Aspaveli's sustained benefits across key markers of disease," said Fadi Fakhouri, M.D., PhD, presenting author, co-lead principal investigator for the VALIANT study, and professor of nephrology at CHUV Lausanne, Switzerland. "Given the high risk of kidney failure, treatment efficacy is incredibly important to C3G and primary IC-MPGN patients, many of whom are in the prime of their lives. These data further underscore the potential of Aspaveli to make a meaningful difference for patients." In patients who switched from placebo to Aspaveli at the start of the open-label period, Aspaveli demonstrated a similar magnitude of benefit in proteinuria reduction and stabilization of kidney function. Nils Kinnman, MD, PhD, Head of Medical Affairs and Clinical Development, Sobi said, "The results from the Phase 3 VALIANT study underscore the potential of Aspaveli in addressing the urgent needs of patients living with the kidney diseases C3G and primary IC-MPGN. This study is an example of Sobi's commitment to advance innovative therapies that make a meaningful difference in patients' lives." "These data reinforce the strength of the EMPAVELI efficacy and safety profile across a broad population of patients with C3G and primary IC-MPGN, including adults and adolescents with native and post-transplant kidney disease," said Peter Hillmen, M.B., Ch.B., Ph.D., chief medical advisor, rare disease, Apellis. "With an FDA decision this summer, we look forward to bringing EMPAVELI to patients living with these rare and severe kidney diseases as quickly as possible." EMPAVELI/Aspaveli showed favorable safety and tolerability, consistent with its established profile. There were no new safety signals. Eight presentations highlight substantial clinical advances in rare kidney disease A total of eight presentations, including six on podium, will be highlighted at the meeting. The presentations will showcase clinically meaningful results from the Phase 3 VALIANT study, among other data. Additionally, two abstracts were selected by congress organizers as Top 10 best ERA abstracts. The "Top 10" are deemed significant studies underlining the growing field of clinical research in kidney disease. About C3 Glomerulopathy (C3G) and Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) C3G and primary IC-MPGN are rare and debilitating kidney diseases that can lead to kidney failure. Excessive C3 deposits are a key marker of disease activity, which can lead to kidney inflammation, damage, and failure. Approximately 50% of people living with C3G and primary IC-MPGN suffer from kidney failure within five to 10 years of diagnosis, requiring a burdensome kidney transplant or lifelong dialysis.1 Additionally, approximately 90% of patients who previously received a kidney transplant will experience disease recurrence.2 The diseases are estimated to affect 5,000 people in the United States and up to 8,000 in Europe.3 About the VALIANT Study The VALIANT Phase 3 study (NCT05067127) is a randomized, placebo-controlled, double-blinded, multi-center study designed to evaluate pegcetacoplan efficacy and safety in 124 patients who are 12 years of age and older with C3G or primary IC-MPGN. It is the largest single trial conducted in these populations and the only study to include adolescent and adult patients with native and post-transplant kidneys. Study participants were randomized to receive pegcetacoplan or placebo twice weekly for 26 weeks. Following this 26-week randomized controlled period, patients were able to proceed to a 26-week open-label phase in which all patients received pegcetacoplan. The primary endpoint of the study was the log transformed ratio of urine protein-to-creatinine ratio (UPCR) at Week 26 compared to baseline. About Pegcetacoplan in Rare Diseases Pegcetacoplan is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, a part of the body's immune system, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is under investigation for rare diseases across hematology and nephrology. Pegcetacoplan is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) as EMPAVELI®/Aspaveli® in the United States, European Union, and other countries globally. About the Apellis and Sobi Collaboration Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, and Apellis has exclusive U.S. commercialization rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy. About Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at and LinkedIn. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit or follow us on X (Twitter) and LinkedIn. Apellis Forward-Looking Statement Apellis Forward-Looking Statement Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding plans to submit applications for regulatory approval for the treatment of patients with C3G and IC-MPGN. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whethersystemic pegcetacoplan will receive approval for those indications from the FDA or equivalent foreign regulatory agencies when expected or at all; and any other factors discussed in the "Risk Factors" section of Apellis' Annual Report on Form 10-K with the Securities and Exchange Commission on February 28, 2025 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Contacts SobiFor details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. Contacts Apellis Media:Tracy Vineis,media@ Neil Carnahan, CFA, References 1. C3 glomerulopathy. National Institute of Health, Genetics Home Reference. Accessed November 21, 2019. 2. Tarragón, B, et al. C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First 2 Years after Transplantation. Clinical Journal of the American Society of Nephrology. August 2024; 19(8)1005-1015. doi: 10.2215/CJN.0000000000000474. 3. Data on file using literature consensus. This information was brought to you by Cision The following files are available for download: Sobi and Apellis Aspaveli Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases View original content: Sign in to access your portfolio